Warren Phipps1, Edith Nakku-Joloba2, Elizabeth M Krantz3, Stacy Selke4, Meei-Li Huang4, Fred Kambugu5, Jackson Orem6, Corey Casper7, Lawrence Corey8, Anna Wald9. 1. Department of Medicine Division of Vaccine and Infectious Disease. 2. College of Health Sciences, Makerere University STD Clinic/Ward 12, Mulago Hospital, Kampala, Uganda. 3. Division of Vaccine and Infectious Disease. 4. Department of Laboratory Medicine. 5. STD Clinic/Ward 12, Mulago Hospital, Kampala, Uganda. 6. Uganda Cancer Institute College of Health Sciences, Makerere University. 7. Department of Medicine Department of Epidemiology Department of Global Health, University of Washington Division of Vaccine and Infectious Disease Division of Clinical Research Division of Public Health Science, Fred Hutchinson Cancer Research Center, Seattle, Washington. 8. Department of Medicine Department of Laboratory Medicine Division of Vaccine and Infectious Disease Division of Clinical Research. 9. Department of Medicine Department of Laboratory Medicine Department of Epidemiology Division of Vaccine and Infectious Disease.
Abstract
BACKGROUND: Despite the high prevalence of herpes simplex virus type 2 (HSV-2) in sub-Saharan Africa, the natural history of infection among Africans is not well characterized. We evaluated the frequency of genital HSV shedding in HIV-seropositive and HIV-seronegative men and women in Uganda. METHODS: Ninety-three HSV-2-seropositive Ugandan adults collected anogenital swab specimens for HSV DNA quantification by polymerase chain reaction 3 times daily for 6 weeks. RESULTS: HSV-2 was detected from 2484 of 11 283 swab specimens collected (22%), with a median quantity of 4.3 log10 HSV copies/mL (range, 2.2-8.9 log10 HSV copies/mL). Genital lesions were reported on 749 of 3875 days (19%), and subclinical HSV shedding was detected from 1480 of 9113 swab specimens (16%) collected on days without lesions. Men had higher rates of total HSV shedding (relative risk [RR], 2.0 [95% confidence interval {CI}, 1.3-2.9]; P < .001); subclinical shedding (RR, 1.7 [95% CI, 1.1-2.7]; P = .01), and genital lesions (RR, 2.1 [95% CI, 1.2-3.4]; P = .005), compared with women. No differences in shedding rates or lesion frequency were observed based on HIV serostatus. CONCLUSIONS: HSV-2 shedding frequency and quantity are high among HSV-2-seropositive adults in sub-Saharan Africa, including persons with and those without HIV infection. Shedding rates were particularly high among men, which may contribute to the high prevalence of HSV-2 and early acquisition among African women.
BACKGROUND: Despite the high prevalence of herpes simplex virus type 2 (HSV-2) in sub-Saharan Africa, the natural history of infection among Africans is not well characterized. We evaluated the frequency of genital HSV shedding in HIV-seropositive and HIV-seronegative men and women in Uganda. METHODS: Ninety-three HSV-2-seropositive Ugandan adults collected anogenital swab specimens for HSV DNA quantification by polymerase chain reaction 3 times daily for 6 weeks. RESULTS:HSV-2 was detected from 2484 of 11 283 swab specimens collected (22%), with a median quantity of 4.3 log10 HSV copies/mL (range, 2.2-8.9 log10 HSV copies/mL). Genital lesions were reported on 749 of 3875 days (19%), and subclinical HSV shedding was detected from 1480 of 9113 swab specimens (16%) collected on days without lesions. Men had higher rates of total HSV shedding (relative risk [RR], 2.0 [95% confidence interval {CI}, 1.3-2.9]; P < .001); subclinical shedding (RR, 1.7 [95% CI, 1.1-2.7]; P = .01), and genital lesions (RR, 2.1 [95% CI, 1.2-3.4]; P = .005), compared with women. No differences in shedding rates or lesion frequency were observed based on HIV serostatus. CONCLUSIONS:HSV-2 shedding frequency and quantity are high among HSV-2-seropositive adults in sub-Saharan Africa, including persons with and those without HIV infection. Shedding rates were particularly high among men, which may contribute to the high prevalence of HSV-2 and early acquisition among African women.
Authors: Christine Johnston; Jia Zhu; Lichen Jing; Kerry J Laing; Christopher M McClurkan; Alexis Klock; Kurt Diem; Lei Jin; Jeffrey Stanaway; Elizabeth Tronstein; William W Kwok; Meei-Li Huang; Stacy Selke; Youyi Fong; Amalia Magaret; David M Koelle; Anna Wald; Lawrence Corey Journal: J Virol Date: 2014-02-19 Impact factor: 5.103
Authors: Nicholas J Van Wagoner; William M Geisler; James M Sizemore; Richard Whitley; Edward W Hook Journal: Sex Transm Dis Date: 2010-04 Impact factor: 2.830
Authors: Lyana Rodrigues Pinto Lima; Amanda Perse da Silva; Jonas Schmidt-Chanasit; Vanessa Salete de Paula Journal: Mem Inst Oswaldo Cruz Date: 2017-02-16 Impact factor: 2.743
Authors: David I Bernstein; Rhonda D Cardin; Derek A Pullum; Fernando J Bravo; Konstantin G Kousoulas; David A Dixon Journal: PLoS One Date: 2019-03-27 Impact factor: 3.240
Authors: Alisha Chetty; Matthew G Darby; Pia M Vornewald; Mara Martín-Alonso; Anna Filz; Manuel Ritter; Henry J McSorley; Lindi Masson; Katherine Smith; Frank Brombacher; Matthew K O'Shea; Adam F Cunningham; Bernhard Ryffel; Menno J Oudhoff; Benjamin G Dewals; Laura E Layland; William G C Horsnell Journal: Cell Host Microbe Date: 2021-04-14 Impact factor: 21.023
Authors: Romain Silhol; Helen Coupland; Rebecca F Baggaley; Lori Miller; Lisa Staadegaard; Sami L Gottlieb; James Stannah; Katherine M E Turner; Peter Vickerman; Richard Hayes; Philippe Mayaud; Katharine J Looker; Marie-Claude Boily Journal: J Acquir Immune Defic Syndr Date: 2021-09-01 Impact factor: 3.771
Authors: Laura Matrajt; Soren Gantt; Bryan T Mayer; Elizabeth M Krantz; Jackson Orem; Anna Wald; Lawrence Corey; Joshua T Schiffer; Corey Casper Journal: Sci Rep Date: 2017-10-12 Impact factor: 4.379
Authors: Katharine Jane Looker; Christine Johnston; Nicky J Welton; Charlotte James; Peter Vickerman; Katherine M E Turner; Marie-Claude Boily; Sami L Gottlieb Journal: BMJ Glob Health Date: 2020-03-08